Preclinical developments in type 2 diabetes.

[1]  P. J. Larsen,et al.  Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. , 2001, Diabetes.

[2]  D. Drucker.  Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. , 2001, Current pharmaceutical design.

[3]  J. Mccormack,et al.  Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. , 2001, Current pharmaceutical design.

[4]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[5]  G. Shulman,et al.  Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.

[6]  P. Damsbo,et al.  Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. , 2001, Diabetes care.

[7]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[8]  K. Yamazaki,et al.  Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. , 2001, Biochemical and biophysical research communications.

[9]  J. Holst,et al.  Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. , 2001, Diabetes care.

[10]  Martin M. Matzuk,et al.  Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2 , 2001, Science.

[11]  J. Holst,et al.  Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. , 2001, Diabetes.

[12]  B. Friedrichsen,et al.  Regulation of beta-cell mass by hormones and growth factors. , 2001, Diabetes.

[13]  Jie Zhou,et al.  Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. , 2000, Endocrinology.

[14]  D. Drucker,et al.  Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[15]  J. Holst,et al.  Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. , 2000, European journal of pharmacology.

[16]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[17]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Holst,et al.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. , 2000, Diabetes.

[19]  S. Chirala,et al.  The subcellular localization of acetyl-CoA carboxylase 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Drucker,et al.  Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling1. , 2000, Endocrinology.

[21]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[22]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[23]  J. Holst,et al.  Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.

[24]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[25]  C. Schmitz‐Peiffer,et al.  Ceramide Generation Is Sufficient to Account for the Inhibition of the Insulin-stimulated PKB Pathway in C2C12 Skeletal Muscle Cells Pretreated with Palmitate* , 1999, The Journal of Biological Chemistry.

[26]  S. Germain,et al.  Encapsulated, Genetically Engineered Cells, Secreting Glucagon‐like Peptide‐1 for the Treatment of Non‐insulin‐dependent Diabetes Mellitus , 1999, Annals of the New York Academy of Sciences.

[27]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[28]  R. Pederson,et al.  Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. , 1999, Metabolism: clinical and experimental.

[29]  K. H. Kim,et al.  Roles of acetyl-CoA carboxylase beta in muscle cell differentiation and in mitochondrial fatty acid oxidation. , 1999, Biochemical and biophysical research communications.

[30]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[31]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[32]  M. Nauck.  Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective , 1998, Acta Diabetologica.

[33]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[34]  R. Pederson,et al.  Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.

[35]  J. Ha,et al.  Evidence that acetyl-CoA carboxylase isoforms play different biological roles in H9c2 cardiomyocyte. , 1998, Biochemical and biophysical research communications.

[36]  J. Holst,et al.  GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions , 1997, Diabetes Care.

[37]  Z. Bloomgarden.  New therapeutic approaches to non-insulin-dependent diabetes mellitus. , 1997, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[38]  W. Malaisse,et al.  Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats , 1997, Diabetes.

[39]  S. Lillioja,et al.  Skeletal Muscle Triglyceride Levels Are Inversely Related to Insulin Action , 1997, Diabetes.

[40]  B. Göke,et al.  Blood Glucose Lowering and Glucagonostatic Effects of Glucagon-Like Peptide I in Insulin-Deprived Diabetic Dogs , 1997, Diabetes.

[41]  S. Wakil,et al.  Human Acetyl-CoA Carboxylase 2 , 1997, The Journal of Biological Chemistry.

[42]  E. Kraegen,et al.  Alterations in the Expression and Cellular Localization of Protein Kinase C Isozymes ε and θ Are Associated With Insulin Resistance in Skeletal Muscle of the High-Fat–Fed Rat , 1997, Diabetes.

[43]  K. Kim,et al.  Acetyl-CoA carboxylase is essential for nutrient-induced insulin secretion. , 1996, Biochemical and biophysical research communications.

[44]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[45]  A. Hamsten,et al.  The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients , 1996, Diabetes Care.

[46]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[47]  K. H. Kim,et al.  Cloning of human acetyl-CoA carboxylase-beta and its unique features. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  R. Pederson,et al.  Investigation of Glucose-dependent Insulinotropic Polypeptide(1-42) and Glucagon-like Peptide-1-(7-36) Degradation in Vitro by Dipeptidyl Peptidase IV Using Matrix-assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry , 1996, The Journal of Biological Chemistry.

[49]  J. Holst,et al.  Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet , 1996, Diabetes Care.

[50]  M. Prentki,et al.  Are the β-Cell Signaling Molecules Malonyl-CoA and Cystolic Long-Chain Acyl-CoA Implicated in Multiple Tissue Defects of Obesity and NIDDM? , 1996, Diabetes.

[51]  G. Boden,et al.  Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. , 1995, The Journal of clinical investigation.

[52]  K. Midthjell,et al.  Hypoglycemia and Insulin Pumps , 1995, Diabetes Care.

[53]  P. Wahl,et al.  Earlier Appearance of Impaired Insulin Secretion Than of Visceral Adiposity in the Pathogenesis of NIDDM: 5-Year Follow-up of Initially Nondiabetic Japanese-American Men , 1995, Diabetes Care.

[54]  R. Shulman,et al.  Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[56]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[57]  J. W. Gronwald.  Herbicides inhibiting acetyl-CoA carboxylase. , 1994, Biochemical Society transactions.

[58]  L. Rossetti,et al.  Mechanisms of fatty acid-induced inhibition of glucose uptake. , 1994, The Journal of clinical investigation.

[59]  B. Spiegelman,et al.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. DeFronzo,et al.  Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. , 1993, The Journal of clinical investigation.

[61]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[62]  M. Mozzoli,et al.  Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. , 1991, The Journal of clinical investigation.

[63]  L. Mandarino,et al.  Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. , 1990, The Journal of clinical investigation.

[64]  S. Wakil,et al.  Acute hormonal control of acetyl-CoA carboxylase. The roles of insulin, glucagon, and epinephrine. , 1990, The Journal of biological chemistry.

[65]  J. Bar-Tana,et al.  Inhibition of rat liver acetyl-CoA carboxylase by β,β′-tetramethyl-substituted hexadecanedioic acid (MEDICA 16) , 1990 .

[66]  R. Henry,et al.  Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. , 1990, The Journal of clinical investigation.

[67]  T. Watts,et al.  Identification of an isozymic form of acetyl-CoA carboxylase. , 1990, The Journal of biological chemistry.

[68]  K. Thampy.  Formation of malonyl coenzyme A in rat heart. Identification and purification of an isozyme of A carboxylase from rat heart. , 1989, The Journal of biological chemistry.

[69]  R. DeFronzo,et al.  Oxidative and non-oxidative glucose metabolism in non-obese Type 2 (non-insulin-dependent) diabetic patients , 1988, Diabetologia.

[70]  T. Watts,et al.  Insulin stimulates the dephosphorylation and activation of acetyl-CoA carboxylase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Bar-Tana,et al.  Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes. , 1985, The Journal of biological chemistry.

[72]  R. Denton,et al.  Evidence that insulin activates fat-cell acetyl-CoA carboxylase by increased phosphorylation at a specific site. , 1982, The Biochemical journal.

[73]  R. Harris,et al.  Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. , 1979, The Journal of biological chemistry.

[74]  M. Maragoudakis.  Inhibition of hepatic acetyl coenzyme A carboxylase by hypolipidemic agents. , 1969, The Journal of biological chemistry.

[75]  O. H. Lowry,et al.  Kinetic evidence for multiple binding sites on phosphofructokinase. , 1966, The Journal of biological chemistry.

[76]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[77]  J. Tepperman,et al.  Effects of antecedent food intake pattern on hepatic lipogenesis. , 1958, The American journal of physiology.

[78]  M. Andrews,et al.  Aspirin and Diabetes Mellitus , 1957, British medical journal.

[79]  R. Williamson,et al.  On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate , 1901, British medical journal.

[80]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[81]  Lenhard Jm.  PPAR gamma/RXR as a molecular target for diabetes. , 2001 .

[82]  G. Holländer,et al.  Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage. , 2000, Diabetes.

[83]  C. Durinx,et al.  Natural substrates of dipeptidyl peptidase IV. , 2000, Advances in experimental medicine and biology.

[84]  Demetrios Vavvas,et al.  Malonyl-CoA, fuel sensing, and insulin resistance. , 1999, American journal of physiology. Endocrinology and metabolism.

[85]  K. Kim,et al.  Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a pancreatic beta-cell line. , 1998, Cellular signalling.

[86]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[87]  J. Casida,et al.  Coenzyme A esters of 2-aryloxyphenoxypropionate herbicides and 2-arylpropionate antiinflammatory drugs are potent and stereoselective inhibitors of rat liver acetyl-CoA carboxylase. , 1992, Life sciences.

[88]  R. Mentlein,et al.  The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. , 1990, Biological chemistry Hoppe-Seyler.

[89]  R. Denton,et al.  5 Acetyl-Coenzyme A Carboxylase , 1987 .

[90]  S. Wakil,et al.  Fatty acid synthesis and its regulation. , 1983, Annual review of biochemistry.

[91]  O. Wieland.  The mammalian pyruvate dehydrogenase complex: structure and regulation. , 1983, Reviews of physiology, biochemistry and pharmacology.

[92]  G. Hardie.  Fat and phosphorylation - the role of covalent enzyme modification in lipid synthesis , 1981 .

[93]  J. Moss,et al.  Acetyl coenzyme A carboxylase. , 1974, Current topics in cellular regulation.